{"id":16655,"date":"2023-07-03T11:45:00","date_gmt":"2023-07-03T03:45:00","guid":{"rendered":"https:\/\/flcube.com\/?p=16655"},"modified":"2024-12-04T11:54:13","modified_gmt":"2024-12-04T03:54:13","slug":"rarestone-groups-pitolisant-earns-priority-review-status-for-narcolepsy-treatment-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=16655","title":{"rendered":"RareStone Group&#8217;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China"},"content":{"rendered":"\n<p>The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a China-based rare disease specialist formerly known as Citrine Medicine, has secured priority review status for its in-licensed drug candidate, pitolisant. This status is awarded for the drug&#8217;s potential as a treatment for excessive daytime drowsiness (EDS) or cataplexy in adolescents and children over 6 years old with narcolepsy, highlighting the drug&#8217;s potential as a pediatric drug as noted by the CDE. <\/p>\n\n\n\n<p><strong>Mechanism of Action and Impact of Pitolisant<\/strong><br>Pitolisant is a selective histamine 3 (H3) receptor antagonist\/inverse agonist that increases the synthesis and release of histamine, a neurotransmitter that promotes arousal in the brain. By enhancing the activity of histaminergic neurons, pitolisant improves the consciousness and alertness of patients. This mechanism of action makes it a promising treatment for narcolepsy, a condition characterized by EDS and sudden episodes of muscle weakness, or cataplexy. <\/p>\n\n\n\n<p><strong>Regulatory Milestones and Market Access<\/strong><br>The drug has already been approved in the EU and US to treat episodic sleeping sickness with or without sudden onset cataplexy, with approvals in March 2016 and August 2019, respectively. Pitolisant obtained breakthrough therapy designation in the US in 2020. RareStone entered into a licensing deal with France-based Bioprojet Pharma in 2020, securing development rights for the drug in China. It was first prescribed in Boao of Hainan province in May 2021. The market filing for pitolisant was accepted for review by the National Medical Products Administration (NMPA) two months later, signaling a potential path to market approval and access for patients in China.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2599,91,80,24,739],"class_list":["post-16655","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-bioprojet-pharma","tag-boao-lecheng-pilot-zone","tag-priority-reviews","tag-rare-orphan-disease-drugs","tag-rarestone"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>RareStone Group&#039;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a China-based rare disease specialist formerly known as Citrine Medicine, has secured priority review status for its in-licensed drug candidate, pitolisant. This status is awarded for the drug&#039;s potential as a treatment for excessive daytime drowsiness (EDS) or cataplexy in adolescents and children over 6 years old with narcolepsy, highlighting the drug&#039;s potential as a pediatric drug as noted by the CDE.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=16655\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"RareStone Group&#039;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=16655\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-07-03T03:45:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-04T03:54:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16655#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16655\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"RareStone Group&#8217;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China\",\"datePublished\":\"2023-07-03T03:45:00+00:00\",\"dateModified\":\"2024-12-04T03:54:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16655\"},\"wordCount\":271,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Bioprojet Pharma\",\"Boao Lecheng pilot zone\",\"Priority reviews\",\"Rare \\\/ orphan disease drugs\",\"RareStone\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16655#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16655\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=16655\",\"name\":\"RareStone Group's Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-07-03T03:45:00+00:00\",\"dateModified\":\"2024-12-04T03:54:13+00:00\",\"description\":\"The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a China-based rare disease specialist formerly known as Citrine Medicine, has secured priority review status for its in-licensed drug candidate, pitolisant. This status is awarded for the drug's potential as a treatment for excessive daytime drowsiness (EDS) or cataplexy in adolescents and children over 6 years old with narcolepsy, highlighting the drug's potential as a pediatric drug as noted by the CDE.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16655#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=16655\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=16655#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"RareStone Group&#8217;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"RareStone Group's Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China - Insight, China&#039;s Pharmaceutical Industry","description":"The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a China-based rare disease specialist formerly known as Citrine Medicine, has secured priority review status for its in-licensed drug candidate, pitolisant. This status is awarded for the drug's potential as a treatment for excessive daytime drowsiness (EDS) or cataplexy in adolescents and children over 6 years old with narcolepsy, highlighting the drug's potential as a pediatric drug as noted by the CDE.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=16655","og_locale":"en_US","og_type":"article","og_title":"RareStone Group's Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=16655","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-07-03T03:45:00+00:00","article_modified_time":"2024-12-04T03:54:13+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=16655#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=16655"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"RareStone Group&#8217;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China","datePublished":"2023-07-03T03:45:00+00:00","dateModified":"2024-12-04T03:54:13+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=16655"},"wordCount":271,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Bioprojet Pharma","Boao Lecheng pilot zone","Priority reviews","Rare \/ orphan disease drugs","RareStone"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=16655#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=16655","url":"https:\/\/flcube.com\/?p=16655","name":"RareStone Group's Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-07-03T03:45:00+00:00","dateModified":"2024-12-04T03:54:13+00:00","description":"The Center for Drug Evaluation (CDE) website in China has indicated that RareStone Group, a China-based rare disease specialist formerly known as Citrine Medicine, has secured priority review status for its in-licensed drug candidate, pitolisant. This status is awarded for the drug's potential as a treatment for excessive daytime drowsiness (EDS) or cataplexy in adolescents and children over 6 years old with narcolepsy, highlighting the drug's potential as a pediatric drug as noted by the CDE.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=16655#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=16655"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=16655#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"RareStone Group&#8217;s Pitolisant Earns Priority Review Status for Narcolepsy Treatment in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16655","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16655"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16655\/revisions"}],"predecessor-version":[{"id":16659,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/16655\/revisions\/16659"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16655"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16655"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16655"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}